Qiagen NV
$ 37.06
-0.96%
12 Jun - close price
- Market Cap 7,643,625,000 USD
- Current Price $ 37.06
- High / Low $ 37.22 / 36.80
- Stock P/E 18.91
- Book Value 16.15
- EPS 1.96
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date 2026-07-14
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 57.82
- 52 Week Low 32.53
About
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Analyst Target Price
$43.82
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-04 | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-31 | 2024-04-29 | 2024-02-06 | 2023-10-30 | 2023-08-08 |
| Reported EPS | 0.54 | 0.62 | 0.64 | 0.63 | 0.58 | 0.64 | 0.62 | 0.6 | 0.5 | 0.6 | 0.56 | 0.57 |
| Estimated EPS | 0.54 | 0.62 | 0.62 | 0.63 | 0.54 | 0.65 | 0.59 | 0.56 | 0.47 | 0.6 | 0.54 | 0.56 |
| Surprise | 0 | 0 | 0.02 | 0 | 0.04 | -0.01 | 0.03 | 0.04 | 0.03 | 0 | 0.02 | 0.01 |
| Surprise Percentage | 0% | 0% | 3.2258% | 0% | 7.4074% | -1.5385% | 5.0847% | 7.1429% | 6.383% | 0% | 3.7037% | 1.7857% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.61 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|
| Payment Date | None | 2025-07-10 | None | None |
| Amount | $2.29 | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | N/A |
| Dividend Yield | 0% |
| Next Dividend Date | 2026-07-14 |
| Ex-Dividend Date | 2026-07-07 |
Recent News: QGEN
2026-06-13 09:39:58
QIAGEN N.V. (QGEN) announced a release according to Article 40, Section 1 of the WpHG (German Securities Trading Act), based on a notification from the AFM. The notification details Goldman Sachs Group Inc.'s voting rights in QIAGEN N.V. as of June 9, 2026, showing a total capital interest and voting rights of 2.82%, held indirectly through various financial instruments.
2026-06-12 20:08:42
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM. The announcement details changes in share and voting rights holdings for Norges Bank as of June 9, 2026. QIAGEN N.V. explicitly states it is not responsible for the accuracy of the notification, which is taken from the AFM's public register.
2026-06-12 07:45:32
The article provides a sector overview of Qiagen N.V., a diagnostics and life-science tools provider, focusing on its position in the competitive molecular testing market. It highlights Qiagen's "Sample to Insight" approach, its dual-market strategy serving molecular diagnostics and life sciences, and its reliance on recurring revenue from consumables. The piece also discusses the challenges and opportunities for Qiagen, including competition, regulatory landscapes, and the need to expand non-COVID test menus.
2026-06-10 20:10:55
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM (the Netherlands Authority For the Financial Markets) on June 10, 2026. The notification details Goldman Sachs Group Inc., The as the entity obliged to notify, outlining various types of shares and derivatives held, and their corresponding voting rights and capital interest in QIAGEN N.V. The total capital interest and voting rights held by Goldman Sachs Group Inc., The, through various indirect channels, are reported at 3.24%.
2026-06-10 20:10:55
QIAGEN N.V. (QGEN) has released a notification regarding voting rights as per Article 40, Section 1 of the WpHG. The notification, disclosed by the AFM, details Goldman Sachs Group Inc.'s holdings in QIAGEN N.V., including various types of shares and derivatives, and specifies the distribution of capital interest and voting rights held indirectly.
2026-06-08 18:10:29
Qiagen N.V. recently released its latest quarterly figures and an updated outlook, keeping the diagnostics specialist in the spotlight for investors. The company's core business involves providing solutions for molecular diagnostics and sample preparation, with a significant portion of its revenue being recurring. Qiagen is adapting its portfolio post-pandemic to focus on broader molecular testing workflows and non-pandemic applications, while also investing in digital solutions and bioinformatics.
